Overexpression of CD85j in TNBC patients inhibits Cetuximab-mediated NK-cell ADCC but can be restored with CD85j functional blockade.
Roberti MP, Juliá EP, Rocca YS, Amat M, Bravo AI, Loza J, Coló F, Loza CM, Fabiano V, Maino M, Podhorzer A, Fainboim L, Barrio MM, Mordoh J, Levy EM.
Roberti MP, et al. Among authors: mordoh j.
Eur J Immunol. 2015 May;45(5):1560-9. doi: 10.1002/eji.201445353. Epub 2015 Apr 7.
Eur J Immunol. 2015.
PMID: 25726929
Free article.